SGLT2i + GLP-1RA Combo May Halve MACE Risk: Largest Real-World Analysis Tags SGLT-2 Inhibitor Read more about SGLT2i + GLP-1RA Combo May Halve MACE Risk: Largest Real-World Analysis
Lower Tumor Incidence Observed With SGLT2 Inhibitors in T2DM Tags SGLT-2 Inhibitor Read more about Lower Tumor Incidence Observed With SGLT2 Inhibitors in T2DM
Enavogliflozin Add-On to Insulin Lowers HbA1c Without Added Safety Risk in T2DM Tags SGLT-2 Inhibitor Read more about Enavogliflozin Add-On to Insulin Lowers HbA1c Without Added Safety Risk in T2DM
Empagliflozin Improves Beta Cell Function Compared With Insulin in T2DM Tags SGLT-2 Inhibitor Read more about Empagliflozin Improves Beta Cell Function Compared With Insulin in T2DM
Metabolic Risk Reduction Achieved After Kidney Transplant With GLP-1 and SGLT2 Agents Tags SGLT-2 Inhibitor Read more about Metabolic Risk Reduction Achieved After Kidney Transplant With GLP-1 and SGLT2 Agents
SGLT2 Inhibitors Improve Outcomes in CKD Regardless of Diabetes or Albuminuria Severity Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Improve Outcomes in CKD Regardless of Diabetes or Albuminuria Severity
SGLT2 Inhibitors Show Greater Treatment Persistence Than GLP-1 RAs in T2DM Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Show Greater Treatment Persistence Than GLP-1 RAs in T2DM
Incretin Therapies Show Modest Biliary Disease Risk Without Pancreatitis Concern Tags Dopamine-D2 receptor agonist SGLT-2 Inhibitor Read more about Incretin Therapies Show Modest Biliary Disease Risk Without Pancreatitis Concern
Among Antidiabetic Drugs, SGLT2 Inhibitors Linked to the Lowest Dementia Risk in T2DM Tags SGLT-2 Inhibitor Read more about Among Antidiabetic Drugs, SGLT2 Inhibitors Linked to the Lowest Dementia Risk in T2DM
SGLT2 Inhibitors Linked to Consistent Cardioprotection Regardless of Revascularization Status Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Linked to Consistent Cardioprotection Regardless of Revascularization Status